{"filing":{"accession_number":"0001193125-26-284002","cik":"0001631574","ticker":"WVE","company_name":"Wave Life Sciences Ltd.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"d70732d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526284002/d70732d8k.htm"},"events":[{"id":14123,"run_id":12562,"accession_number":"0001193125-26-284002","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 discloses the results of a special shareholder meeting held on June 22, 2026, where shareholders voted on the Scheme of Arrangement to approve Wave Life Sciences' redomiciliation from Singapore to another jurisdiction. The filing reports final voting results (155,190,836 shares voted in favor, 78,429 against, with 87 shareholders voting in favor and 0 against), which is the core disclosure required under Item 5.07. The redomiciliation is a material corporate restructuring requiring court and shareholder approval.","company_name":"Wave Life Sciences Ltd.","ticker":"WVE","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11467,"accession_number":"0001193125-26-284002","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a special shareholder meeting held on June 22, 2026, where shareholders voted on the Scheme of Arrangement to approve Wave Life Sciences' redomiciliation from Singapore to another jurisdiction. The filing reports final voting results (155,190,836 shares voted in favor, 78,429 against, with 87 shareholders voting in favor and 0 against), which is the core disclosure required under Item 5.07. The redomiciliation is a material corporate restructuring requiring court and shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:30:38.238235+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11467,"accession_number":"0001193125-26-284002","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a special shareholder meeting held on June 22, 2026, where shareholders voted on the Scheme of Arrangement to approve Wave Life Sciences' redomiciliation from Singapore to another jurisdiction. The filing reports final voting results (155,190,836 shares voted in favor, 78,429 against, with 87 shareholders voting in favor and 0 against), which is the core disclosure required under Item 5.07. The redomiciliation is a material corporate restructuring requiring court and shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:30:38.238235+00:00","company_name":"Wave Life Sciences Ltd.","ticker":"WVE","filing_date":"2026-06-26"}]}